# Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

> **NCT03113422** · PHASE2 · COMPLETED · sponsor: **PrECOG, LLC.** · enrollment: 56 (actual)

## Conditions studied

- Follicular Lymphoma
- Non-Hodgkin's Lymphoma Follicular
- Non-Hodgkin's Lymphoma, Adult High Grade

## Interventions

- **DRUG:** Induction Venetoclax
- **DRUG:** Maintenance Venetoclax

## Key facts

- **NCT ID:** NCT03113422
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-27
- **Primary completion:** 2021-05-03
- **Final completion:** 2023-01-06
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113422, "Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03113422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*